ATI-1777 a topical JAK1/3 inhibitor may benefit atopic dermatitis without systemic drug exposure, results from preclinical development and Phase 2a randomized-control study ATI-1777-AD-201

Autor: Changelian, Paul, Xu, Canxin, Mnich, Steve, Hope, Heidi, Kostecki, Kourtney, Hirsch, Jeff, Loh, Chin-Yi, Anderson, David, Blinn, James, Hockerman, Susan, Dick, Evan, Smith, Walter, Monahan, Joseph, Raoof, Tooraj, Forman, Seth, Burt, David, Barnes, Brad, Gordon, David, Walker, Neal, Sudzina, John, Tucker, Stephen, Jacobsen, Jon
Zdroj: JID Innovations; 20230101, Issue: Preprints
Abstrakt: Atopic dermatitis (AD), a chronic, pruritic skin disease, affects 10%-30% of children and up to 14% of adults in developed countries. ATI-1777, a potent and selective JAK1/3 inhibitor, was designed with multiple sites of metabolism to deliver local efficacy in the skin and limit systemic exposure. In preclinical studies, ATI-1777 selectively inhibited JAK1/3 with limited systemic exposure and without any adverse effects.
Databáze: Supplemental Index